Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06900595 · ClinicalTrials.gov registry record · Phase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
A Phase 2 study of Recurrent Adrenal Cortical Carcinoma and Locally Advanced Adrenal Cortical Carcinoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT06900595 is a Phase 2 study of Recurrent Adrenal Cortical Carcinoma and Locally Advanced Adrenal Cortical Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06900595, a Phase 2 study of Recurrent Adrenal Cortical Carcinoma and Locally Advanced Adrenal Cortical Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- BIOLOGICAL Cemiplimab
- DRUG Cabozantinib
Study Locations (20)
Illinois
- Lurie Children's Hospital-Chicago - Chicago
- Northwestern University - Chicago
- Northwestern Medicine Cancer Center Kishwaukee - DeKalb
- Northwestern Medicine Cancer Center Delnor - Geneva
- Northwestern Medicine Glenview Outpatient Center - Glenview
- Northwestern Medicine Grayslake Outpatient Center - Grayslake
- Northwestern Medicine Lake Forest Hospital - Lake Forest
- Northwestern Medicine Oak Brook - Oak Brook
- Northwestern Medicine Orland Park - Orland Park
- Memorial Hospital East - Shiloh
- Northwestern Medicine Cancer Center Warrenville - Warrenville
Missouri
- Siteman Cancer Center at Saint Peters Hospital - City of Saint Peters
- Siteman Cancer Center at West County Hospital - Creve Coeur
- CoxHealth South Hospital - Springfield
- Washington University School of Medicine - St Louis
- Siteman Cancer Center-South County - St Louis
- Siteman Cancer Center at Christian Hospital - St Louis
California
- UC San Diego Moores Cancer Center - La Jolla
Massachusetts
- Dana-Farber Cancer Institute - Boston
Nebraska
- Nebraska Medicine-Bellevue - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-02-22 |
| Est. Completion | 2029-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06900595
The ClinicalTrials.gov registry entry for NCT06900595 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Adrenal Cortical Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06900595 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT06900595 about?
NCT06900595 is a clinical study titled "Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer". This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvemen...
What is the current status of trial NCT06900595?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2026-02-22. Estimated completion is 2029-06-02.
What conditions does trial NCT06900595 study?
This clinical trial studies the following conditions: Recurrent Adrenal Cortical Carcinoma, Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8.
What interventions are being tested in trial NCT06900595?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Cemiplimab (BIOLOGICAL), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT06900595?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06900595 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adrenal Cortical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Adrenal Cortical Carcinoma
All registered trials for this condition
Locally Advanced Adrenal Cortical Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.